Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: Benefits of mortality reduction versus risk of fatal intussusception

Vaccine

Volumn 27, Issue 22, 2009, Pages 2916-2922

  Patel, Manish M ^a   Clark, Andrew D ^b   Glass, Roger I ^a   Greenberg, Harry ^c   Tate, Jacqueline ^a   Santosham, Mathuram ^d   Sanderson, Colin F B ^b   Steele, Duncan ^e   Cortese, Margaret ^a   Parashar, Umesh D ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Program for Appropriate Technology in Health   (United States)

Author keywords

Diarrhea; Mortality; Rotavirus; Vaccine coverage; Vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ROTAVIRUS VACCINE;

ARTICLE; CHILD; DEVELOPING COUNTRY; FATALITY; GROUPS BY AGE; HUMAN; INFANT; INTUSSUSCEPTION; MAJOR CLINICAL STUDY; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; ROTAVIRUS; SENSITIVITY ANALYSIS; VACCINATION; VIRUS INFECTION;

CHILD, PRESCHOOL; DEVELOPING COUNTRIES; HUMANS; INFANT; INFANT, NEWBORN; INTUSSUSCEPTION; RISK ASSESSMENT; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 65049090757     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.016     Document Type: Article

References (40)

1. Parashar U.D., Gibson C.J., Bresse J.S., and Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 12 February (2) (2006) 304-306
2. World Health Organization (WHO). Global and national estimates of deaths under age five attributable to rotavirus infection: 2004 (as of 31 March 2006). Available at: http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/ [Last accessed June 16, 2008].
3. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 344 8 (2001 Feb 22) 564-572
4. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 January (1) (2006) 11-22
5. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 January (1) (2006) 23-33
6. Glass R.I., Parashar U.D., Bresee J.S., Turcios R., Fischer T.K., Widdowson M.A., et al. Rotavirus vaccines: current prospects and future challenges. Lancet 368 July (9532) (2006) 323-332
7. Simonsen L., Viboud C., Elixhauser A., Taylor R.J., and Kapikian A.Z. More on RotaShield and intussusception: the role of age at the time of vaccination. J Infect Dis 192 September (Suppl. 1) (2005) S36-S43
8. Tate J.E., Simonsen L., Viboud C., Steiner C., Patel M.M., Curns A.T., et al. Trends in intussusception hospitalizations among US infants, 1993-2004: implications for monitoring the safety of the new rotavirus vaccination program. Pediatrics 121 May (5) (2008) e1125-e1132
9. Global Advisory Committee on Vaccine Safety, 1-2 December 2005. Wkly Epidemiol Rec 2006;81(January (2)):15-9.
10. Gargiullo P.M., Murphy T.V., and Davis R.L. Is there a safe age for vaccinating infants with tetravalent rhesus-human reassortant rotavirus vaccine?. J Infect Dis 194 December (12) (2006) 1793-1794 [author reply 4-5]
11. Rothman K.J., Young-Xu Y., and Arellano F. Age dependence of the relation between reassortant rotavirus vaccine (RotaShield) and intussusception. J Infect Dis 193 March (6) (2006) 898 [author reply 9]
12. WHO. Rotavirus vaccines. Weekly Epidemiol Rec 82 August (32) (2007) 285-295
13. Tai J.H., Curns A.T., Parashar U.D., Bresee J.S., and Glass R.I. Rotavirus vaccination and intussusception: can we decrease temporally associated background cases of intussusception by restricting the vaccination schedule?. Pediatrics 118 August (2) (2006) e258-e264
14. Madhi S, Lerumo T, Louw C, Kirsten M, Neuzil K, Steele D, et al. Efficacy of human rotavirus vaccine RIX4414 (Rotarix™) in South African infants during the first year of life-an interim report. Presented at the 8th international rotavirus syposium. Istanbul, Turkey, June 3; 2008 [abstract].
15. DHS (ENDES), Programa DHS/Macro International Inc., MD, USA; 2000. Available at: http://www.measuredhs.com [last accessed June 16, 2008].
16. Available at http://esa.un.org/unpp/index.asp [last accessed June 16, 2008].
17. Rheingans RD, Antil L, Podewils LJ, Bresse JS, Parashar UD. Healthcare costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. J Infect Dis, in press.
18. Vesikari T, Dennehy P, Matson D, Itzler R, Dallas M, Goveia MG, et al. Efficacy of pentavalent rotavirus vaccine, RotaTeq, between doses: potential benefits of early protection. Presented at the 8th international rotavirus syposium. Istanbul, Turkey, June 3-4; 2008 [abstract].
19. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370 November (9601) (2007) 1757-1763
20. Vesikari T, Matson D, Dennehy P, Dallas M, Itzler R, Dinubile M, et al. Efficacy of the pentavalent rotavirus vaccine in subjects after 1 or 2 doses in the rotavirus efficacy & safety trial (REST). Presented at the 44th annual meeting of the Infectious Disease Society of America. Toronto, Ontario, Canada, October 12-15; 2006 [abstract].
21. Haber P., Patel M., Izurieta H.S., Baggs J., Gargiullo P., Weintraub E., et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 121 June (6) (2008) 1206-1212
22. WHO. Acute intussusception in infants and children. Incidence, clinical presentation and management: a global perspective (2002), World Health Organization, Geneva p. 1-98 [Document WHO/V & B/02.19].
23. Abate H., Linhares A.C., Venegas G., Vergara R.F., Lopez P., Jimenez E., et al. A multi-center study of intussusception in Latin America: first year results. Presented at: ICP. August 15-20, Cancun, Mexico (2004) [abstract]
24. Buettcher M., Baer G., Bonhoeffer J., Schaad U.B., and Heininger U. Three-year surveillance of intussusception in children in Switzerland. Pediatrics 120 September (3) (2007) 473-480
25. Chen Y.E., Beasley S., and Grimwood K. Intussusception rotavirus associated hospitalisation in New Zealand. Arch Dis Child 90 October (10) (2005) 1077-1081
26. Fischer T.K., Bihrmann K., Perch M., Koch A., Wohlfahrt J., Kare M., et al. Intussusception in early childhood: a cohort study of 1.7 million children. Pediatrics 114 September (3) (2004) 782-785
27. Gay N., Ramsay M., and Waight P. Rotavirus vaccination and intussusception. Lancet 354 September (9182) (1999) 956
28. Ho W.L., Yang T.W., Chi W.C., Chang H.J., Huang L.M., and Chang M.H. Intussusception in Taiwanese children: analysis of incidence, length of hospitalization and hospital costs in different age groups. J Formos Med Assoc=Taiwan yi zhi 104 June (6) (2005) 398-401
29. Justice F., Carlin J., and Bines J. Changing epidemiology of intussusception in Australia. J Paediatr Child Health 41 September-October (9-10) (2005) 475-478
30. Nelson E.A., Tam J.S., Glass R.I., Parashar U.D., and Fok T.F. Incidence of rotavirus diarrhea and intussusception in Hong Kong using standardized hospital discharge data. Pediatr Infect Dis J 21 July (7) (2002) 701-703
31. O'Ryan M., Lucero Y., Pena A., and Valenzuela M.T. Two year review of intestinal intussusception in six large public hospitals of Santiago, Chile. Pediatr Infect Dis J 22 August (8) (2003) 717-721
32. Perez-Schael I., Escalona M., Salinas B., Materan M., Perez M.E., and Gonzalez G. Intussusception-associated hospitalization among Venezuelan infants during 1998 through 2001: anticipating rotavirus vaccines. Pediatr Infect Dis J 22 March (3) (2003) 234-239
33. Saez-Llorens X., and Guevara J.N. Intussusception and rotavirus vaccines: what is the background risk?. Pediatr Infect Dis J 23 April (4) (2004) 363-365
34. Ball L.K., Evans G., and Bostrom A. Risky business: challenges in vaccine risk communication. Pediatrics 101 March (3 Pt 1) (1998) 453-458
35. Bauch C.T., and Earn D.J. Vaccination and the theory of games. Proc Natl Acad Sci USA 101 September (36) (2004) 13391-13394
36. Connolly T., and Reb J. Omission bias in vaccination decisions: where's the "omission"? Where's the "bias"?. Org Behav Hum Dec Process 91 July (2) (2003) 186-202
37. Weijer C. The future of research into rotavirus vaccine. BMJ 321 September (7260) (2000) 525-526
38. WHO. Report of the meeting on future direction for rotavirus vaccine research in developing countries. Geneva: World Health Organization; 2000. p. 1-56 [Document WHO/V & B/00.23]
39. Murphy B.R., Morens D.M., Simonsen L., Chanock R.M., La Montagne J.R., and Kapikian A.Z. Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. J Infect Dis 187 April (8) (2003) 1301-1308
40. Delayed onset and diminished magnitude of rotavirus activity-United States, November 2007-May 2008. Morbidity and Mortality Weekly Report 2008 June 27;57(25):697-700.